Avenue Therapeutics Inc. (ATXI) shares were falling -52.46% to trade at $0.29 in pre-market at last check. Avenue Therapeutics (ATXI) stock lost -1.55% to close Tuesday’s session at $0.61. The stock volume remained 0.47 million shares, which was higher than the average daily volume of 0.24 million shares within the past 50 days. ATXI shares have fallen by -88.60% over the last 12 months, and they have moved down by -15.52% in the past week.

Over the past three months, the stock has lost -55.80%, while over the past six months, it has shed -62.58%. Further, the company has a current market of $11.12 million and its outstanding shares stood at 16.63 million. Avenue Therapeutics Inc.(ATXI) stock is losing ground after the company’s meeting with the Federal Drug Administration (FDA).

What Avenue Therapeutics Inc.(ATXI) has talked about with the FDA?

Avenue Therapeutics (ATXI) is a specialty drug organization whose mission is to foster IV tramadol, a potential elective that could lessen the utilization of ordinary narcotics, for patients experiencing intense torment in the U.S. Road is settled in New York City.

Avenue Therapeutics (ATXI) yesterday declared the result of the FDA joint gathering of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol.

In the last piece of the public gathering, the Advisory Committee casted a ballot yes or no on the accompanying inquiry:

“Has the Applicant submitted sufficient data to help the place that the advantages of their item offset the dangers for the administration of intense agony adequately extreme to require a narcotic pain relieving in an ongoing setting?”

The outcomes are 8 yes votes and 14 no votes. FDA Advisory Committees furnish the FDA with free exhortation and non-restricting proposals.

The FDA has recently expressed that contribution from an Advisory Committee is required for the Office of New Drugs (“OND”) to arrive at a choice on ATXI’s proper debate goal demand (“FDRR”) and that the OND will react to Avenue Therapeutics (ATXI) FDRR inside 30 schedule days after the Advisory Committee meeting.

Halting of stock trading:

Avenue Therapeutics (ATXI) in a different news yesterday reported that NASDAQ has ended exchanging of the ATXI normal stock.